Perdagangan BioNTech BNTX

Jual
 Beli

BioNTech diagram langsung

5m 15m 30m 1h 4h 1d 1w

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Berita Terkini

Tampilkan lebih banyak
Tommy Yap 2025 Jul 12, 21:00

 Week Ahead: Inflation Data from U.S., Canada, and U.K. Take Centre Stage

Forex Indices
N/A
Ava Grace 2025 Jul 11, 09:21

EU-US Trade Talks: Progress, Challenges, and Future Prospects

N/A
Emma Rose 2025 Jul 11, 09:21

Elon Musk, Tesla Stock, and Political Ambitions: A Rocky Road Ahead?

N/A
Noah Lee 2025 Jul 11, 09:21

Iranian President Claims Israel Attempted Assassination Amidst Nuclear Program Tensions

N/A
Sophia Claire 2025 Jul 11, 09:20

Fed Debate Heats Up: Navigating Trump Tariffs and Interest Rate Decisions

N/A
Emma Rose 2025 Jul 11, 09:20

Trump's Tariff Barrage: Brazil Faces 50% Levy and Market Jitters

N/A
liam james 2025 Jul 11, 09:20

Fed Minutes: Tariffs, Inflation, and the Interest Rate Outlook

N/A
liam james 2025 Jul 11, 09:20

OpenAI's AI-Powered Browser: A Challenge to Google Chrome's Dominance

Info

Spread

0.7779

Spread (%)

0.6909 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar tutup

Senin

13:31 - 19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Kamis

13:31-19:59

Jumat

13:31-19:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

27138191360

Saham yang Beredar

240395008

Tanggal Penghasilan (Berikutnya)

0000-00-00

Hasil Div

2022-06-17

Tanggal Non-Dividen

2022-06-02

Proyeksi tingkat dividen tahunan

0

Proyeksi hasil dividen tahunan

0

EPS

-3.74

Pelajari lebih lanjut tentang instrumen ini

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Instrumen Terkait

Aset
Jual
Beli
Ubah (%)

Lakukan Trading

Lakukan Trading

Lakukan Trading

Lakukan Trading
view_all_instruments

latest_education_articles

Tampilkan lebih banyak
Trustpilot